BCTG Acquisition Corp.
Completed
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $125M
- Underwriters
- Focus
- Biotech
- SEC Filings
- 1819133
- Public Embarc Page
- https://embarc.com/capital/spac/1819133/BCTG/bctg-acquisition
- IPO Ticker
- BCTG
SPAC Leadership
Information on the SPAC leadership.
- Chairman, Chief Executive OfficerAaron I. Davis
- President, DirectorChristopher Fuglesang, Ph.D.
- Chief Financial Officer, TreasurerMichael Beauchamp
- Chief Operating Officer, SecretaryAndrew Ellis, M.D.
- DirectorCarole L. Nuechterlein
- DirectorRichard Heyman, Ph.D.
- DirectorCharles M. Baum, M.D., Ph.D.
- DirectorJamie G. Christensen, Ph.D.
Target Information
Information on the SPAC target for merger.
- Company
- Tango Therapeutics
- Presentation
- Investor Presentation (SEC) on 2021-04-14
- New Ticker
- TNGX
- Description
- Tango Therapeutics is "a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines."